Treatment & Research Archives

May 13, 2022

ASH 2021: Dr. Jennifer Woyach with an Update on Ibrutinib vs. Chemoimmunotherapy as a Frontline Treatment for Chronic Lymphocytic Leukemia

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Anthony Mato interviewed Dr. Jennifer Woyach. They discussed updated results from the Alliance A041202 trial, which now has longer-term follow-up data.

May 6, 2022

Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for CLL/SLL from the informCLL Real-World Registry

Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.

April 29, 2022

ASH 2021: Dr. Constantine Tam on Novel BCL2 Inhibitor BGB-11417 For Patients with Relapsed/Refractory B-Cell Malignancies

April 28, 2022

Why Do These Matter in CLL: Long-term Data, Side-Effect Management, and Staying Healthy?

Recorded on April 28, 2022 Join CLL Society and PlatformQ Health for this on-demand educational session consisting of 3 chapters: Getting Up-to-Speed on New Data Managing Side Effects of BTK Inhibitors: What, When, How, and WhoTips to Stay on the Patient/Caregiver ‘A Game’ Jennifer Woyach, MD, professor at The

April 13, 2022

ASH 2021: Dr. Constantine Tam on BTK Inhibitor TG-1701 for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

At the American Society of Hematology (ASH) 2021, Dr. Alan Skarbnick, Director of the CLL program at Novant Health Cancer Institute in Charlotte, NC, interviewed Dr. Constantine Tam, a hematologist at the Peter McCallum Cancer Center in Melbourne, Australia. They discussed the results of a phase 1 clinical trial

April 13, 2022

Dr. Andrea Sitlinger on High-Intensity Interval Training for Older Adults with Chronic Lymphocytic Leukemia (CLL)

Our own Dr. Brian Koffman spoke with Dr. Andrea Sitlinger, Assistant Professor of Medicine and hematologist at Duke Cancer Center in Durham, NC. They talked about the results of a pilot study on high-intensity interval training for older adults with CLL or SLL.

April 8, 2022

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Oral Treatments in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the 2-year results of the Captivate Study evaluating outcomes in previously untreated CLL patients

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

Treatment & Research

ASH 2021: Dr. Jennifer Woyach with an Update on Ibrutinib vs. Chemoimmunotherapy as a Frontline Treatment for Chronic Lymphocytic Leukemia

Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for CLL/SLL from the informCLL Real-World Registry

ASH 2021: Dr. Constantine Tam on Novel BCL2 Inhibitor BGB-11417 For Patients with Relapsed/Refractory B-Cell Malignancies

Why Do These Matter in CLL: Long-term Data, Side-Effect Management, and Staying Healthy?

ASH 2021: Dr. Constantine Tam on BTK Inhibitor TG-1701 for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Dr. Andrea Sitlinger on High-Intensity Interval Training for Older Adults with Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Oral Treatments in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT